This new device is now able to measure head as well as eye movements, allowing a more precise evaluation of markers of brain functions during oculomotor examinations
EyeBrain, which develops markers of cerebral function for neurological and psychiatric conditions, today announces the launch of a new medical device, the EyeBrain T2. This new device will be used during examinations of ocular motricity, the motor system controlling eye movements. The main characteristic of this new oculometer is that it also records head movements.
The EyeBrain T2 is therefore more effective and more sensitive than its predecessor, the Mobile EBT (Mobile EyeBrain Tracker). By recording both eye movements and head movements, it is now possible to determine the patient’s gaze during his examination.
This technological innovation not only allows for more precise measurements, but it will also enable additional examinations for neurologists. These examinations are essential because they provide new markers of cerebral function, allowing neurologists to refine their diagnoses and to track the development of neurological and psychiatric conditions in their patients. The EyeBrain T2 device is also easier for practitioners to work with, thanks to its improved ergonomic design: the EyeBrain T2 is lighter and more comfortable than its predecessor. Moreover, its software is reviewed regularly in order to be practitioner-friendly.
“With the EyeBrain T2, medical professionals now have access to one of the most powerful medical devices for use in oculomotor examinations,” said Serge Kinkingnehun, CEO of EyeBrain. “The fact that head movements can now be taken into account during these examinations is a true innovation.”
The use of oculomotricity as a marker of cerebral function presents a range of advantages for specialists. As a method which combines simplicity, speed, precision, and is non-invasive, it has the ability to save medical practitioners a significant amount of time in the early diagnosis of certain neurological illnesses. These can include Parkinsonian syndromes, tracking the development of multiple sclerosis, or in characterizing reading disorders. It also enables practitioners to assess the impact of the therapies offered to patients.
EyeBrain expects sales figures to double for the new device compared to its predecessor, with around 15 EyeBrain T2 units expected to be sold over the next six months. Around thirty units of the previous device have been sold over the last two years.
“We have already received several orders for the EyeBrain T2, and we are very optimistic about sales figures for this device,” said Serge Kinkingnehun. “We have noticed that it is not only sparking interest amongst academics, but also in the French government, by encouraging the development of companies focusing on an aging population, which will enhance the silver economy.”
With this new device, EyeBrain primarily intends to strengthen its presence in Europe and North Africa. In the longer term, the company plans to distribute its EyeBrain Trackers to the Asian market.
EyeBrain will present a series of new oculomotor tests at the end of 2013. These new tests will make it possible to identify new brain markers which will aid in the diagnosis of new pathologies in the neurological and psychiatric fields. The company is also working on new devices for use in doctors’ offices.
For more information, visit www.eye-brain.com.